Bristol Myers Squibb (BMY) Bets On AI Drug Discovery And Wider Trial Access

Bristol Myers Squibb (NYSE:BMY) has entered multi year AI drug development partnerships with Pathos AI and Tempus AI. The agreement gives Bristol Myers Squibb exclusive access to Pathos AI's discovery platform for neuroscience projects. Tempus AI will provide multi year data licensing that connects real world patient information with AI tools across Bristol Myers Squibb's pipeline. The company also launched a national collaboration with the Institute for Healthcare Improvement to broaden...